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ARTICLE
Neurokinin-3 receptor activation selectively
prolongs atrial refractoriness by inhibition
of a background K+ channel
Marieke W. Veldkamp1, Guillaume S.C. Geuzebroek2, Antonius Baartscheer1, Arie O. Verkerk3,
Cees A. Schumacher1, Gedeon G. Suarez4, Wouter R. Berger1, Simona Casini1, Shirley C.M. van Amersfoorth1,
Koen T. Scholman3, Antoine H.G. Driessen5, Charly N.W. Belterman1, Antoni C.G. van Ginneken3,
Joris R. de Groot1, Jacques M.T. de Bakker1, Carol Ann Remme1, Bas J. Boukens3 & Ruben Coronel1,6
The cardiac autonomic nervous system (ANS) controls normal atrial electrical function. The
cardiac ANS produces various neuropeptides, among which the neurokinins, whose actions
on atrial electrophysiology are largely unknown. We here demonstrate that the neurokinin
substance-P (Sub-P) activates a neurokinin-3 receptor (NK-3R) in rabbit, prolonging action
potential (AP) duration through inhibition of a background potassium current. In contrast,
ventricular AP duration was unaffected by NK-3R activation. NK-3R stimulation lengthened
atrial repolarization in intact rabbit hearts and consequently suppressed arrhythmia duration
and occurrence in a rabbit isolated heart model of atrial ﬁbrillation (AF). In human atrial
appendages, the phenomenon of NK-3R mediated lengthening of atrial repolarization was
also observed. Our ﬁndings thus uncover a pathway to selectively modulate atrial AP duration
by activation of a hitherto unidentiﬁed neurokinin-3 receptor in the membrane of atrial
myocytes. NK-3R stimulation may therefore represent an anti-arrhythmic concept to sup-
press re-entry-based atrial tachyarrhythmias, including AF.
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Normal atrial electrophysiology is critically controlledby the cardiac autonomic nervous system (ANS), whichmodulates heart rate, excitability, conduction and
refractoriness1,2. The cardiac ANS plays a key role in the genesis
of malignant atrial arrhythmias, particularly atrial ﬁbrillation
(AF)3–7. The major neurotransmitters that mediate the control
of cardiac electrophysiological properties are the classical neu-
rotransmitters acetylcholine (ACh) and noradrenalin (NA).
However, the intracardiac ganglia located in fat pads on the
heart produce a variety of neuropeptides including substance-P
(Sub-P)8–11, in addition to NA and ACh. While the actions of
these neuropeptides on the cardiac neuron as effector cell are
subject of ongoing investigation, their direct effects on atrial
cardiomyocyte electrophysiology are largely unknown. This is
relevant considering the potential role of neuropeptides in
arrhythmogenesis as they may constitute targets for anti-
arrhythmic therapy. Current therapeutic approaches in AF are
aimed at prolonging action potential duration and consequently
increasing refractoriness of atrial tissue, thereby reducing the
susceptibility for re-entrant based arrhythmias12,13. However,
clinical success rate is often diminished by the limited selectivity
for atrial tissue, potentially leading to ventricular pro-arrhythmia
secondary to action potential prolongation in this cardiac
compartment12,13.
Substance-P14 belongs to the tachykinin peptide family. It
exerts its biological effects by binding to one or more of three
distinct types of neurokinin receptors (NK-1R, NK-2R and NK-
3R), with a preferential binding for NK-1R15,16. Sub-P is widely
distributed in the cardiovascular system and is involved in the
regulation of many physiological functions, including heart rate
(through stimulation of cholinergic neurons) and blood
pressure17,18. Reduced Sub-P content has been associated with AF
incidence19,20. Speciﬁcally, the occurrence of post-operational AF
was associated with decreased Sub-P serum levels in patients who
had undergone coronary artery bypass surgery19. Furthermore,
degeneration of Sub-P immuno-reactive nerves has been reported
in a dog model of AF20. These observations imply that intact Sub-
P levels protect against the development of AF. However, a direct
action of Sub-P on atrial myocardial electrophysiology has thus
far not been identiﬁed.
In this study, we investigated the electrophysiological effects of
the neuropeptide Sub-P in isolated rabbit atrial myocytes, and in
Langendorff-perfused and in situ rabbit hearts. We show that
Sub-P produces a selective prolongation of atrial AP duration and
refractoriness in a dose-dependent manner. Importantly, these
effects were also present at high pacing rates (typically observed
in AF), and were absent in ventricular myocardium, indicating
atrial-speciﬁc efﬁcacy. We demonstrate that these effects are
mediated through activation of the neurokinin-3 receptor (NK-
3R) and involve inhibition of a background K+ current. In a
rabbit isolated heart model of AF, NK-3R stimulation produced a
strong anti-arrhythmic effect by reducing AF duration and inci-
dence. We therefore propose NK-3R as a therapeutic target for re-
entry-based atrial arrhythmias, including AF.
Results
Sub-P prolongs the action potential in atrial cardiomyocytes.
Figure 1 illustrates that application of substance-P (Sub-P; 1 µM)
resulted in signiﬁcant action potential (AP) prolongation (Fig. 1a)
in an isolated rabbit atrial cardiomyocyte. The average effects
(mean ± SEM) of Sub-P (1 µM) on AP duration at 20%, 50% and
90% of repolarization (APD20, APD50 and APD90) in cardio-
myocytes stimulated at 1 Hz are summarized in Fig. 1b. APD50
(Control: 21.2 ± 7.5 vs. Sub-P: 43.4 ± 14.6 ms, p < 0.05) and
APD90 (Control: 89.0 ± 2.0 vs. Sub-P: 125.2 ± 2.5 ms, p < 0.001)
were statistically signiﬁcantly increased following Sub-P applica-
tion. Sub-P furthermore reduced the resting membrane potential
(RMP) (Control: −81.0 ± 1.5 vs. Sub-P: −75.0 ± 2.1 mV, p < 0.05,
Fig. 1c, Table 1) and the action potential amplitude (APA)
(Control: 108.6 ± 3.4 mV vs. Sub-P: 97.0 ± 6.1 mV, p < 0.05,
Fig. 1c, Table 1). A trend towards a concomitant reduction in AP
upstroke velocity (Vmax) was observed following Sub-P applica-
tion (Fig. 1d, Table 1), but this did not reach statistical sig-
niﬁcance due to a large variation between cells.
Sub-P prolonged APD90 in a dose-dependent manner (Fig. 1e).
The increase in APD90 was statistically signiﬁcant at a
concentration of 10 nM Sub-P and higher, and exceeded 20% at
a concentration of 1 µM (Fig. 1e, dotted lines). Sub-P caused a
signiﬁcant AP prolongation at all tested stimulation frequencies
(1, 2, 3 and 4 Hz, Fig. 1f).
Effects of Sub-P on atrial membrane currents. We next inves-
tigated the effects of Sub-P on the major membrane currents
controlling atrial AP duration in rabbit atrial cardiomyocytes,
including steady-state and transient outward currents, L-type
calcium currents, and calcium-dependent currents.
Steady-state and transient outward currents. Representative
examples of current tracings recorded at −120 and +40 mV (see
protocol, Fig. 2a) show a decrease in steady-state outward current
in the presence of Sub-P (10 µM), which was conﬁrmed by the
average current–voltage (I–V) relationships in Fig. 2b. A statis-
tically signiﬁcant decrease in steady-state outward current
was induced at all voltages positive to −50 mV. At +50 mV
the outward current decreased by 20% from 6.9 ± 0.5 pA/pF
(Control) to 5.5 ± 0.6 pA/pF (Sub-P, p < 0.05). In addition, the
inward component of steady-state current at −120 mV was
moderately decreased by Sub-P (Control: −6.8 ± 1.1 vs Sub-P:
−6.0 ± 1.3 pA/pF, p < 0.05).
The resultant I–V curve of the Sub-P sensitive current (Fig. 2c,
grey ﬁlled circles) is virtually linear and has a reversal
potential (dotted line) close to the calculated Nernst potential
for K+ (−85 mV), indicating that it concerns a background
K+ current.
For accurate measurement of the transient outward current
(Ito), blockers of the Na+ current (INa), the L-type calcium
current (ICa,L), and of the slow and rapid components of the
delayed rectiﬁer currents (IKr and IKs) were included in the
various solutions (see Methods section). Figure 2d shows
representative Ito currents upon depolarization to +50 mV,
demonstrating no change in peak currents following application
of Sub-P (10 µM). On average, Sub-P did not affect Ito peak
densities (Fig. 2e) or the time course of current decay at +50 mV
(Table 2), but it caused a small, but signiﬁcant shift in V1/2 of
inactivation by −3.5 mV (Table 2, p < 0.05), as well as a
steepening of the slope of the voltage dependency of activation
(Table 2, p < 0.01). Figure 2f depicts the average I–V relation-
ships, obtained by current amplitude measurement at the end of
the 500 ms voltage steps. Despite the presence of the various ion
channel blockers, Sub-P causes a decrease in the steady-state
inward current from −6.9 ± 1.6 pA/pF to −5.8 ± 1.5 pA/pF at
−120 mV (p < 0.05), and a 25% reduction in steady-state outward
current at +50 mV (Control: 6.1 ± 0.85 vs. Sub-P: 4.6 ± 0.46 pA/
pF, p < 0.05). The Sub-P-sensitive current under these experi-
mental conditions is plotted in Fig. 2c (grey ﬁlled triangles). It
shows an I–V relation similar to the sub-P-sensitive current in the
absence of the various ion channel blockers (Fig. 2c, grey ﬁlled
circles). These data demonstrate that the Sub-P effects on
background current are not mediated by changes in the delayed
rectiﬁer potassium currents IKr and IKs.
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L-type calcium current and calcium-dependent currents. The
representative ICa,L recordings upon a depolarizing pulse to 0 mV
(Fig. 3a, top: voltage protocol) show that peak ICa,L is reduced
following application of Sub-P (10 µM). The average I–V rela-
tionships of ICa,L (Fig. 3b) conﬁrm a statistically signiﬁcant
decrease in peak ICa,L by about 20% from −21 ± 3.3 pA/pF in
Control to –16.6 ± 2.3 pA/pF (p < 0.05) in the presence of Sub-P
at 0 mV, expected to decrease AP duration (contrary to the
observed AP prolonging effect of Sub-P). Neither the voltage
dependencies of (in)activation, nor the time course of current
decay at 0 mV (Table 2) were changed.
Supplementary Figure 1a shows representative examples of
intracellular Ca2+i transients in atrial cardiomyocytes following
ﬁeld stimulation at 5 Hz, before and after application of Sub-P
(10 µM). On average, no differences in diastolic Ca2+i, systolic
Ca2+i or transient amplitude occurred (Supplementary
Figure 1b).
Figure 3c shows a representative example of the Na+–Ca2+
exchange current (INCX) recorded during a descending voltage
ramp protocol (top) before and after application of Sub-P (10
µM). On average, Sub-P had no direct effect on the forward
(inward) or inverse (outward) mode of the INCX (Fig. 3d).
The Ca2+-activated Cl− current (ICl(Ca)) was deﬁned as the
early transient peak amplitude upon depolarizing steps to +30,
+40 and +50 mV (Fig. 3e). Average ICl(Ca) peak amplitudes were
similar before (Control) and after application of Sub-P (Fig. 3f).
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Fig. 1 Effect of substance-P on action potential parameters of rabbit atrial cardiomyocytes. a APs elicited at 1 Hz from an atrial cardiomyocyte under control
conditions and in the presence of 1 µM Sub-P. b–d Bar graph showing average values for AP duration at 20, 50 and 90% of repolarization (APD20, APD50
and APD90) b, resting membrane potential (RMP) and action potential amplitude (APA) c, and maximal upstroke velocity (Vmax) d before (Control) and
after application of 1 µM Sub-P. (N= 4, n= 6, paired t-test.) e Concentration-dependence of APD90 before (Control) and after application of increasing
concentrations of Sub-P. Dotted lines: concentration of Sub-P at which the increase of APD90 exceeded 20%. (N= 4, n= 5, one-way RM ANOVA.)
f Frequency-dependence of APD90 before (Control) and after application of 1 µM Sub-P (N= 4, n= 6, two-way RM ANOVA). All values shown are mean ±
SEM. * P < 0.05
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06530-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4357 | DOI: 10.1038/s41467-018-06530-5 | www.nature.com/naturecommunications 3
Table 1 Effects of substance-P and selective NK-1, NK-2 and NK-3 receptor agonists on action potential parameters in atrial and
ventricular myocytes
RMP (mV) APA (mV) Vmax (V/s) APD20 (ms) APD50 (ms) APD90 (ms)
Atrial myocyte
Control −81.0 ± 1.5 108.6 ± 3.5 290.5 ± 57.9 5.1 ± 1.4 21.2 ± 7.5 89.0 ± 2.0
Sub-P (1 µM, n= 6) −75.0 ± 2.1a 97.0 ± 6.1a 236.7 ± 88.7 16.0 ± 7.0 43.4 ± 14.6a 125.2 ± 2.5a
Control −82.4 ± 1.1 106.0 ± 2.4 238.6 ± 35.2 4.8 ± 0.6 14.2 ± 3.1 73.7 ± 3.1
[Sar9,Met(O2)11]-SP (100 nM, n= 7) −79.9 ± 1.7 101.8 ± 5.4 252.1 ± 72.9 5.0 ± 0.3 18.8 ± 3.9 72.7 ± 4.3
Control −81.6 ± 1.1 111.5 ± 2.3 281.6 ± 57.6 4.1 ± 1.2 25.0 ± 13.3 98.4 ± 10.3
(b-Ala)-NKA (4-10) (100 nM, n= 4) −79.0 ± 2.2 100.9 ± 6.1 255.1 ± 87.0 6.2 ± 1.4 35.1 ± 14.7 105.2 ± 10.4
Control −82.7 ± 1.2 109.9 ± 2.6 259.9 ± 47.8 6.7 ± 1.3 27.9 ± 7.2 95.8 ± 11.3
Senktide (100 nM, n= 16) −80.6 ± 1.5 104.0 ± 4.3 259.7 ± 39.2 11.3 ± 2.9 64.5 ± 7.5a 143.9 ± 9.0a
Ventricular myocyte
Control −85.9 ± 1.2 121.6 ± 1.6 260.4 ± 55.3 67.0 ± 9.4 140.4 ± 11.6 176.0 ± 10.6
Sub-P (1 µM, n= 9) −86.5 ± 1.2a 122.3 ± 1.8 300.0 ± 53.0a 65.9 ± 9.4 137.5 ± 11.3 171.8 ± 10.1
Control −86.4 ± 0.4 120.8 ± 1.3 267.7 ± 45.9 59.8 ± 7.9 134.3 ± 8.3 170.4 ± 7.4
Senktide (100 nM, n= 10) −86.7 ± 0.6 121.1 ± 1.4 298.0 ± 41.6a 56.8 ± 9.4 128.9 ± 10.4 166.2 ± 8.6
All values are mean ± SEM
RMP: resting membrane potential, APA: action potential amplitude, Vmax: upstroke velocity, APD20: action potential duration at 20% repolarization, APD50: action potential duration at 50%
repolarization, APD90: action potential duration at 90% repolarization
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However, Sub-P reduced steady-state outward currents at the end
of the 250 ms depolarizing steps by ~25% (Supplementary
Figure 2; Control: 7.2 ± 0.8 pA/pF vs. Sub-P: 5.7 ± 0.5, Vm=+
50 mV, p < 0.05). Data points for the Sub-P-sensitive current at
+30, +40 and +50 mV are included in the I–V relation of Fig. 2c
(black ﬁlled squares), and show complete overlap with the Sub-P-
sensitive current in the absence of ion channel blockers. Since ICl
(Ca) measurements were performed in the presence of 2 mM
4-AP, the effect of Sub-P is not mediated by a reduction in
sustained component of Ito or IKur.
Taken together, these data indicate that Sub-P acts through
inhibition of a K+ background current in rabbit atrial myocytes.
Neurokinin-3 receptor mediates action potential prolongation.
To deﬁne the neurokinin receptor (NK-R) subtype mediating the
AP prolonging effect produced by Sub-P, we examined the effect
of various NK receptor subtype selective agonists on AP duration
in isolated rabbit atrial cardiomyocytes. Fig. 4a, b (left panels)
show representative APs at 2 Hz before (Control) and after
application of the NK-1R agonist [Sar9,Met(O2)11]-SP (100 nM),
and the NK-2R agonist (β-Ala)-NKA(4-10) (100 nM), respec-
tively. Administration of NK-1R and NK-2R agonists did not
signiﬁcantly alter AP morphology or duration (Fig. 4a, b (right
panels), Table 1). In contrast, application of 100 nM of the NK-3R
agonist Senktide (Fig. 4c) signiﬁcantly prolonged APD50 (Con-
trol: 27.9 ± 7.2 vs. Senktide: 64.5 ± 7.5 ms, p < 0.001) and APD90
(Control: 95.8 ± 11.3 vs. Senktide: 143.9 ± 9.0 ms, p < 0.001).
Senktide (100 nM) prolonged APD50 and APD90 by 130% and
50%, respectively, but did not alter other AP parameters
(Table 1). To rule out the possibility of a time-dependent increase
in APD90 contributing to the observed Senktide effect, we per-
formed a set of time-matched controls. Supplementary Figure 3a
shows in a representative example that the APD90 remained
stable during a period of 15 min, whereafter the application of 50
nM Senktide caused a steep increase in APD90. On average,
APD90 remained unchanged at 1, 5 and 10 min (common dura-
tion of the experiment) (Supplementary Figure 3b).
Figure 4d shows the dose-response relationship of Senktide and
atrial APD90. At a concentration of ~10 nM, Senktide induced a
20% increase in APD90 (dotted lines), indicating that it is 100
times more potent than Sub-P (cf. Fig. 1e). Taken together these
data indicate that AP prolongation by Sub-P is consequent to a
reduction in a background K+ current which is mediated through
stimulation of the NK-3 receptor. This was further supported by
the observation that the Senktide-induced AP prolongation was
largely prevented by pre-incubation with the competitive NK-3R
antagonist Osanetant (300 nM) (Fig. 4d). As the AP prolonging
effect of Sub-P is entirely mediated through the NK-3R, we
maintained the use of Senktide—a potent analogue of the
endogenous agonist of the NK-3R (neurokinin B)—in all
following experiments.
Nature of the background K+ current. We next explored the
nature of the background K+ current affected by NK-3 receptor
stimulation. Two-pore-domain potassium (K2P) channels have
been often shown to underlie the background K+ currents in
excitable tissues21. The NK-3 receptor is coupled to the
Gq/11 subgroup of G-proteins22, and several members of the K2P
family are known to be potently inhibited by receptors that signal
through Gq/1123–25. Of those, TREK-1, TASK-1 and TASK-3,
have been shown to be functionally relevant for atrial AP dura-
tion26–28. We therefore considered these 3 channels likely can-
didates for the AP prolonging effect of NK-3 receptor stimulation.
We investigated mRNA expression levels of the different mem-
bers of the K2P channel family as well as the various NK receptor
types in rabbit left atrial myocardium using RNA sequencing. As
shown in Fig. 5a, mRNA expression levels of TACR3 (encoding
NK-3R) were clearly higher than those of TACR1 and TACR2
(encoding NK-1R and NK-2R, respectively). We did not ﬁnd
differences in mRNA expression levels for the different genes
between the left atrial free wall and the left atrial appendage
(Fig. 5a, upper right inset). The presence of NK-3R on the plasma
membrane of rabbit atrial cardiomyocytes was conﬁrmed by
immunohistochemistry (Fig. 5b). The RNA sequencing results
furthermore demonstrated higher expression levels of KCNK3
(encoding TASK-1) in rabbit atrial tissue as compared to KCNK2
(encoding TREK-1) and KCNK9 (encoding TASK-3) (Fig. 5a).
To test the potential contribution of these K2P channels to the
observed effects of NK-3 receptor stimulation, we assessed the
effects of selective blockers for these channels on steady-state
current and AP duration. We ﬁrst examined the effects of ZnCl2
on steady-state outward currents in individual rabbit atrial
cardiomyocytes. Zinc has been reported to be a selective blocker
of TASK-3 channels, but may also inhibit TASK-1 and TREK-1
channels, albeit with lower sensitivities.29–31 As expected, the
average I–V relation in Fig. 6b shows a signiﬁcant decrease in
steady-state outward current at all voltages positive to −60 mV
following Senktide application (50 nM), similar to the effects
observed for Sub-P (Fig. 2b). At +30 mV the outward current
decreased by 44% from 4.6 ± 0.4 pA/pF (Control, n= 8) to 3.2 ±
0.3 pA/pF (Senktide, n= 8, p < 0.05). The Senktide-sensitive I–V
relation (Fig. 6c) is similar to the Sub-P-sensitive current (Fig. 2c),
Table 2 Effects of substance-P (10 µM) on biophysical properties of the L-type calcium current (ICa,L) and the transient outward
current (Ito)
ICa,L-Control ICa,L-Sub-P n Ito-Control Ito-Sub-P n
Current density (pA/pF) −21.3 ± 3.3 −16.6 ± 2.3a 6 9.7 ± 2.9 8.9 ± 2.8 5
Activation
V1/2, mV −15.4 ± 0.8 −17.2 ± 1.4 6 −7.0 ± 7.4 −15.1 ± 3.3 5
k, mV 6.8 ± 0.5 7.0 ± 0.7 6 14.2 ± 0.9 9.8 ± 0.1a 5
Inactivation
V1/2, mV −28.9 ± 1.3 −31.2 ± 2.3 6 −32.5 ± 3.4 −35.9 ± 2.8a 5
k, mV 4.4 ± 0.3 4.9 ± 0.3 6 −5.9 ± 0.9 −5.4 ± 0.2 5
Inactivation time course
τfast, ms 4.4 ± 0.6 4.9 ± 0.7 6 39.6 ± 13.2 41.3 ± 8.1 5
τslow, ms 28.0 ± 3.5 28.2 ± 3.4 6 131.1 ± 33.7 114.6 ± 16.2 5
All values are mean ± SEM. Two-way repeated measures ANOVA followed by pairwise comparison using the Student–Newman–Keuls method= p < 0.05; Compared to control= a
Sub-P: substance-P, V1/2: voltage of half-maximal (in)activation, k: slope factor, tfast and tslow: fast and slow time constants of inactivation
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both in shape and magnitude of current density. The application
of ZnCl2 signiﬁcantly reduced steady-state outward current
(Fig. 6d,e). At +30 mV, the average steady-state outward current
(Fig. 6e) was reduced by 39% from 7.8 ± 0.9 pA (Control, n= 5)
to 5.6 ± 0.8 (ZnCl2, n= 5, p < 0.05). The ZnCl2-sensitive current
(Fig. 6f) was not critically different from the Senktide-sensitive
current (Fig. 6c). In the continued presence of ZnCl2, additional
application of 50 nM Senktide did not further reduce steady-state
outward current (Fig. 6f). These ﬁndings imply that the ZnCl2-
sensitive current and the Senktide-sensitive current are the same,
and possibly carried by either TASK-1, TASK-3 or TREK-1
channels. The selective blockers for TASK-1 (ML-365), TASK-3
(PK-THPP) and TREK-1 (Spadin), all gave a minor prolongation
of the APD90 (Fig. 6g–i). Application of ML-365 gave rise to a 5%
increase in APD90 from 95.6 ± 10.5 ms to 100.4 ± 10.9 ms (Fig. 6j,
n= 8, p < 0.05), PK-THPP application induced an 8% increase
in APD90 from 73.5 ± 3.2 ms to 79.0 ± 3.1 ms (Fig. 6k, n= 7,
p < 0.05), and Spadin application resulted in a 3% increase in
APD90 from 80.1 ± 6.7 ms to 82.1 ± 6.6 ms (Fig. 6l, n= 7, p=NS)
(Supplementary Table 1). Subsequent addition of 50 nM Senktide
in the continued presence of the respective blockers, resulted in a
41% (ML-365), 53% (PK-THHP) and 42% (Spadin) increase in
APD90 (Fig. 6g–l, Supplementary Table 1). These percentages
increase in APD90 induced by Senktide in the presence of the
selective blockers, is in the same order of magnitude as the
increase in APD90 by Senktide alone (Fig. 4d). This implies that
the background current inhibited by NK-3 receptor stimulation is
likely not carried by one of these K+ channels alone.
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Ventricular APD is unaffected by NK-3 receptor stimulation.
We also explored the potential atrial selectivity of NK-3R sti-
mulation, a prerequisite for safe anti-arrhythmic efﬁcacy. We
therefore tested the effects of Sub-P and Senktide on isolated
rabbit ventricular cardiomyocytes. Figure 7a, b shows repre-
sentative ventricular APs at 2 Hz in the absence and in the pre-
sence of the NK-3R agonists Sub-P (1 µM) and Senktide (100
nM), respectively. Neither Sub-P nor Senktide prolonged the
ventricular AP. Overall, no relevant alterations were observed for
the other ventricular AP characteristics on NK-3R stimulation,
except for an increase in Vmax (Table 1, Fig. 7a, b).
NK-3 receptor stimulation prevents atrial ﬁbrillation. To assess
the potential impact of selective NK-3R activation on the in vivo,
whole heart and tissue level, we tested whether NK-3R mediated
AP prolongation is accompanied by an increase in effective
refractory period (ERP) in rabbit intact hearts and human atrial
tissue.
Figure 8a (left panel) shows atrial unipolar electrograms
recorded from a Langendorff-perfused rabbit heart in response to
programmed stimulation at the right atrium, showing a
prolongation of right atrial effective refractory period (AERP)
after addition of the NK-3R agonist (Senktide 20 nM). On
average, right AERP increased from 68.1 ± 5.1 ms at baseline
(Control) to 89.3 ± 6.3 ms after application of 20 nM Senktide
(32% increase; p= 0.00006) (Fig. 8a, right panel). Left AERP,
measured during programmed stimulation at the left atrium,
showed a similar increase in AERP in response to 20 nM Senktide
(Supplementary Figure 5a, b).
We next studied the in vivo response to intravenous Senktide
administration on AERP in open-chested rabbits. Supplementary
Figure 5c shows unipolar electrograms recorded from the left
atrium during programmed stimulation, showing an increased
AERP following infusion of a single bolus of Senktide (11 nmol/
kg). On average, AERP increased from 96.7 ± 13.3 ms to 130.0 ±
20.8 ms after application of Senktide (34% increase; Supplemen-
tary Fig. 5d, p < 0.01).
Similarly, we tested the effect of Senktide on ERP in human
isolated left atrial appendages (LAA) resected from patients with
persistent AF undergoing thoracoscopic surgery for AF. Similar
to rabbit atrial tissue, robust cardiomyocyte plasma membrane
labelling of NK-3R was observed in human LAA tissue (Fig. 5b).
As shown in the example depicted in Fig. 8b (left panel),
superfusion of the LAA preparation (stimulated at BCL 600 ms)
with 100 nM Senktide led to an increase in ERP. Prolongation of
the ERP occurred in all ﬁve human LAAs tested. On average,
Senktide caused an 18.0 ± 0.1% increase of LAA ERP from 201.8
± 6.1 ms (Control) to 237.8 ± 7.5 ms (Senktide) (Fig. 8b, right
panel, n= 5, p= 0.06).
In a rabbit isolated heart model of AF based on atrial dilatation,
we ﬁnally examined whether the increase in AERP resulting from
NK-3 receptor stimulation by Senktide, suppresses AF induci-
bility. Fig. 8c shows representative electrograms recorded from
the left atrium following a burst pacing protocol to provoke AF.
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All electrograms were recorded from the same heart with and
without increased left atrial pressure, and in the absence and
presence of Senktide. In the non-dilated left atrium (0 cm H2O),
burst pacing incidentally elicited short runs of premature atrial
activations (Fig. 8c, upper left). However, in the dilated atrium
where intra-atrial pressure was increased to 20 cm H2O, burst
pacing regularly resulted in episodes of AF (Fig. 8c, lower left).
On average, the total duration of arrhythmia episodes following
each of the 10 consecutive runs of burst pacing, increased from
4.0 ± 0.6 s at 0 cm H2O to 20.6 ± 5.3 s at 20 cm H2O (Fig. 8d, n=
7, p < 0.05, Supplementary Table 2). In the presence of 20 nM
Senktide, however, burst pacing failed to evoke any arrhythmias
in the undilated atrium (Fig. 8c, upper right), and the duration of
the arrhythmia episode was strongly reduced in the dilated atrium
(Fig. 8c, lower right). On average, the total duration of arrhythmia
episodes in the presence of 20 nM Senktide decreased by ~65%
from 4.0 ± 0.6 s to 1.5 ± 0.2 s at 0 cm H2O, and from 20.6 ± 5.3 s
to 6.6 ± 2.5 s at 20 cm H2O (Fig. 8d, n= 7, p < 0.05, Supplemen-
tary Table 2). Senktide not only reduced the duration of the
arrhythmia episodes, but also reduced the AF incidence. Figure 8e
shows that AF incidence in the presence of Senktide was reduced
from 0.08 ± 0.04 to 0.0 ± 0.0 (n= 7, p < 0.05) at 0 cm H2O and
from 0.59 ± 0.09 to 0.17 ± 0.08 at 20 cm H20 (n= 7, p < 0.05),
representing a 70% reduction in AF vulnerability. All effects were
reversible upon wash-out of Senktide, and on normalization of
pressure (Fig. 8d, e, Supplementary Table 2). Thus, by selectively
increasing AERP, NK-3R stimulation strongly reduces AF
inducibility and duration.
Discussion
This study provides biophysical and pharmacological evidence
that the neuropeptide Sub-P prolongs the atrial action potential
in rabbit myocytes by activation of the neurokinin-3 receptor
(NK-3R) and consequent inhibition of a background K+ current.
We further demonstrate that the NK-3R mediated AP pro-
longation is maintained at high pacing rates and results in
increased atrial effective refractory period (ERP) in Langendorff-
perfused and in situ rabbit hearts. Also in human atrial appen-
dages the latter phenomenon was observed. Ventricular action
potential does not change following NK-3R stimulation, indi-
cating atrial-speciﬁc efﬁcacy. In a rabbit isolated heart model of
AF, NK-3R stimulation exerts a potent anti-arrhythmic action by
strongly reducing AF duration and incidence.
The AP prolonging effect by Sub-P was dose-dependent and
occurred at nanomolar concentrations, supporting the view that
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the electrophysiological actions of Sub-P on atrial cardiomyocytes
are receptor-mediated involving the neurokinin cell-surface
receptors15,16. We established that the AP prolongation by Sub-
P was mediated through neurokinin-3 receptor (NK-3R) stimu-
lation, as the selective NK-3R agonist Senktide32 increased APD90
with a 100 times higher potency than Sub-P, while NK-1R and
NK-2R agonists at concentrations that maximally activate their
respective receptors33,34, did not change AP duration. Moreover,
the AP prolongation by NK-3R stimulation was antagonized by
the speciﬁc NK-3R antagonist Osanetant35. The presence of NK-
3R on the surface of atrial cardiomyocytes has thus far not been
demonstrated18. Hoover and Hancock36 were unable to detect
Sub-P binding sites in atria and ventricle of guinea-pig heart. Also
Walsh et al.37 did not ﬁnd evidence for Sub-P binding sites in rat
heart. However, neonatal rat ventricular cardiomyocytes express
mRNA for NK-1R and NK-3R38. RNA-sequencing data and
immunohistochemical analysis in our study further supports the
presence of NK-3R in the sarcolemmal membrane of rabbit and
human atrial cardiomyocytes. Thus, this demonstrates the exis-
tence of NK-3R on adult cardiomyocytes from rabbit and human
atrium and to provide evidence of their functional signiﬁcance.
The RNA sequencing data indicate that the NK-3 receptor is the
dominant neurokinin receptor in atrial cardiomyocytes as mRNA
levels of NK-1R and NK-2R were relatively low. The endogenous
ligand for the NK-3R is neurokinin B (NKB). However, neuro-
kinin A (NKA) and Sub-P, as conﬁrmed in the present study, also
bind to the NK-3R, albeit with different afﬁnities.15,16 All three
neurokinins are produced by neurons of the intrinsic cardiac
nervous system.19,39 The preferential afﬁnity of NK-3R for the
endogenous ligands has a potency order of NKB>NKA>Sub-P,
which implies that NKB may be more relevant for atrial elec-
trophysiology than Sub-P. The exact nature of the effects of NKB/
Sub-P on in vivo atrial electrophysiology are difﬁcult to assess, as
matters are further complicated by the fact that also (cholinergic)
intracardiac neurons possess NK receptors and may release ACh
upon stimulation.40
To our knowledge no data are available concerning the actions
of Sub-P or Senktide on membrane currents in atrial cardio-
myocytes. The main ﬁnding of the present study concerned the
reduction in steady-state outward current in the presence of Sub-
P and Senktide, which is consistent with the observed AP pro-
longation. Other studies have shown that a reduction in sustained
outward current of similar amplitude, has important implications
for atrial AP duration41,42 Changes in outward ICa(Cl), INCX and
Ito do not contribute to AP prolongation, as their current
amplitudes were unchanged in the presence of Sub-P, despite
minor kinetic alterations in the latter. The reduction of ICa,L is not
compatible with AP prolongation by NK-3R stimulation. On the
contrary, a decrease in inward current would shorten the AP.
Evidently, the reduction in steady-state outward current by far
outweighs the effect of ICa,L reduction on AP duration. Detailed
examination of the Sub-P sensitive current indicated that an
outward K+ current is involved, since its reversal potential is close
to the calculated Nernst potential for K+ ions. The steady-state
outward current of atrial myocytes is composed of different types
of K+ currents, including the sustained component of the tran-
sient outward current (Ito), and the slow, rapid and ultra-rapid
components of the delayed rectiﬁer K+ current (IKs, IKr and IKur,
respectively)12,13. Our experiments exclude a decrease in any of
these current types as a possible mechanism underlying the
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observed effects of Sub-P, since the reduction in steady-state
outward current persists in the presence of the respective block-
ers. A candidate underlying the Sub-P mediated effect, is the
background or leakage K+ current, which was also inhibited by
Sub-P in neurons43–45. Recent evidence suggests that members of
the two-pore-domain K+ (K2P) channel family generate the K+
background conductance in excitable tissues21. Neurokinin
receptors are known to be coupled to the Gq/G11 subgroup of G-
proteins22 and several members of the K2P family have been
shown to be potently inhibited by receptors that signal through
Gq/11, including TREK-1, TREK-2, TASK-1 and TASK-323,25. As
TASK-1, TASK-3 and TREK-1 channels have been functionally
identiﬁed in atrial cardiomyocytes to contribute to AP dura-
tion26–28, we considered these channels as candidates for the
action potential prolonging effect. Nevertheless, selective inhibi-
tion of these channels scarcely affected AP duration, which makes
their involvement in isolation unlikely. Application of the non-
speciﬁc channel blocker ZnCl242,46 abolished the inhibition of
the background K+ current by Senktide, and revealed the pre-
sence of a ZnCl2-sensitive component with electrophysiological
characteristics comparable to the Sub-P-sensitive and Senktide-
sensitive currents. However, as zinc modulates the activity of
a broad range of ion channels, the nature of this background
K+ current remains unsure. Future studies dedicated to exact
channel identiﬁcation, are required to designate a particular K+
channel type.
The cardiac autonomic nervous system plays a signiﬁcant role
in the genesis and maintenance of AF. Particularly, alterations in
the sympatho-vagal balance and excessive intrinsic cardiac nerve
activity have been shown to trigger atrial arrhythmias47,48. The
precise role of the various neuropeptides therein is still poorly
understood. In this study, AP prolongation by NK-3R stimulation
in isolated atrial cardiomyocytes (by Sub-P or Senktide) was
reﬂected by an increased atrial effective refractory period (ERP) in
rabbit Langendorff hearts and in situ anaesthetized rabbits, as
well as in human isolated left atrial tissue. An increased ERP
forms an anti-arrhythmic mechanism which may prevent or
terminate AF12,13. To date however, pharmacological interven-
tion aimed at lengthening of atrial repolarization has a limited
applicability due to pro-arrhythmic ventricular side effects
and reverse rate-dependence (i.e., a loss of action at high heart
rates)12,13. As NK-3R stimulation does not prolong the ven-
tricular AP, and prolongs the atrial AP also at high heart rates, it
meets the important prerequisites for a potential atrial-speciﬁc,
anti-ﬁbrillatory action. Indeed we show that NK-3R stimulation
by Senktide in a rabbit isolated heart model of AF based on atrial
dilatation, reduces AF incidence and duration by 70%. Thus, we
demonstrate that the electrophysiological effects of NK-3R sti-
mulation are of potent anti-ﬁbrillatory nature.
In conclusion, this study provides evidence for the functional
expression of the neurokinin-3 receptor in the sarcolemma of
atrial cardiomyocytes. This receptor was known to be expressed
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Senktide (right, N= 5, paired t-test, p= 0.06). c Unipolar electrograms recorded from the left atrium of a rabbit Langendorff-perfused heart following a
burst pacing protocol in the absence (Control, left) and in the presence of 20 nM of the NK-3R agonist Senktide (right), at baseline (0 cm H2O, upper
tracings) and during atrial dilatation (20 cm H2O, lower tracings). d, e Bar graph showing average values for total duration of arrhythmia episodes d and AF
incidence e in Control, after application of 20 nM Senktide, and after wash-out (N= 7, two-way RM ANOVA). All values shown are mean ± SEM. *P < 0.05.
Electrograms: A atrial activation; V ventricular activation; * stimulus
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by neural tissue, but was hitherto unidentiﬁed in cardiac atrial
muscle. Stimulation of NK-3R produces signiﬁcant prolongation
of the atrial but not the ventricular AP through inhibition of a
background K+ channel, possibly a member of the K2P family.
The AP-prolonging action of NK-3R stimulation in the atrium
was also present at high heart rates and greatly reduced AF
inducibility. Hence, we propose NK-3R as a potential anti-
arrhythmic drug target for treatment of AF.
Methods
Animals and human tissue. The study conformed to the ‘Guide for the Care and
Use of Laboratory Animals’ published by the US National Institutes of Health
(NIH Publication No. 85–23, revised 1996) and was approved by the local animal
experiments committee of the Academic Medical Center, Amsterdam, The Neth-
erlands. The study on human atrial appendages was in accordance with the
declaration of Helsinki and was approved by the Institutional Review Board of the
Academic Medical Center, Amsterdam, The Netherlands. All patients gave written
informed consent.
The Langendorff-perfused rabbit heart. Male New Zealand White rabbits
(2.5–3.5 kg) were anaesthetized with 20 mg xylazine and 100 mg ketamine (intra-
muscularly) and heparinized with a bolus of 1000 IU heparin (intravenously).
Subsequently, the animals were killed by 200 mg pentobarbital intravenously, the
thorax was opened and the heart was quickly removed and submerged in ice-cold
perfusion solution (composition see below). After cannulation of the aorta, the
heart was mounted on a Langendorff perfusion setup, and perfused at 37 °C with a
modiﬁed Tyrode’s solution containing (in mmol/L) 128 NaCl, 4.7 KCl, 1.45 CaCl2,
0.6 MgCl2, 27 NaHCO3, 0.4 NaH2PO4 and 11 glucose (pH maintained at 7.4 by
equilibration with a mixture of 95% O2 and 5% CO2)49.
Atrial refractoriness in the Langendorff rabbit heart. Bipolar stimulation- and
unipolar recording electrodes were placed on the left atrial myocardium. The heart
was stimulated at a basic cycle length of 200 ms (cathodal stimulation, 1 ms current
pulse duration, twice the diastolic stimulation threshold). After an equilibrium
period of 30 min, the effective refractory period (ERP) was determined by a train of
16 stimuli at 200 ms followed by a single stimulus with progressively shortened
coupling interval until loss of capture. The ERP was deﬁned as the longest S1–S2
interval without capture. After an equilibrium period of 30 min, wash-in of 20 nM
NK-3R-agonist Senktide was started and ERP measurements were repeated 10 min
following wash-in.
Rabbit isolated heart model of AF based on atrial dilatation. After mounting of
the heart on the Langendorff perfusion setup, a distendable balloon (volume 4–5
ml) connected to a manometer, was inserted through the pulmonary vein openings
into the left atrium, Subsequently, ±0.5 ml saline was injected into the balloon to
yield an intra-atrial pressure of 0 cm H2O (baseline condition). A bipolar pacing
electrode was positioned at the right atrium free wall and the heart was stimulated
at a basic cycle length of 250 ms. Unipolar recording electrodes were positioned on
the left atrium free wall and the left ventricle wall to record atrial and ventricular
electrograms, respectively. The heart was then allowed to equilibrate for a 20-min
period of continuous stimulation, after which right atrial effective refractory period
(AERP) was determined by a train of 8 stimuli at 250 ms followed by a single
stimulus with progressively shortened coupling interval until loss of capture. The
ERP was deﬁned as the longest S1–S2 interval without capture. Subsequently, after
20 stimuli at the basic cycle length (250 ms), a burst pacing protocol consisting of
20 stimuli at 20 Hz (2 ms current pulse duration) was delivered to provoke AF,
followed by a 5 s pause. The protocol to evoke AF was repeated ten times. Next, the
left atrial balloon was distended by injection of 2–4 ml saline up to an intra-atrial
pressure of 20 cm H2O to dilate the atrium, and AERP measurements and burst
pacing protocol to provoke AF were repeated. After a 5 min. recovery period at 0
cm H2O, drug infusion was started and the complete procedure was repeated in the
presence of 20 nM Senktide. Then, a 30 min wash-out period (at intra-atrial
pressure 0 cm H2O) followed, and AERP and AF inducibility were determined
again at intra-atrial pressures of 0 and 20 cm H2O, respectively.
For data analysis we considered three groups: (1) no arrhythmia, (2) an
arrhythmia episode consisting of short runs of premature atrial activations with a
duration Δt <1 s, and (3) an irregular arrhythmia episode with Δt >1 s in duration,
which was deﬁned as AF. To assess the anti-arrhythmic effect of Senktide we
determined the total duration of arrhythmias episodes, which was deﬁned as the
sum of durations of arrhythmia episodes following 10 consecutive burst pacing
protocols, and the AF incidence, which was deﬁned as the fraction of the 10
consecutive burst pacing protocols imposed, that evoked AF.
Left atrial refractoriness in the anaesthetized rabbit. Male New Zealand
White rabbits (2.5–3.5 kg) were anaesthetized with ketamine 50 mg/kg and xylazine
8 mg/kg, and received 0.09 mg/kg Temgesic subcutaneously. The rabbits were
intubated and artiﬁcially ventilated. Anaesthesia was maintained by isoﬂurane
(0.8–1.2%). Catheters for drug infusions and blood pressure recording were
inserted into marginal ear veins and arteries, respectively. Following thoracotomy,
the pericardium was opened and the heart was instrumented as above. When the
rabbit was hemodynamically and electrophysiologically stable, the atrial ERP was
determined by a train of 8 stimuli at 220 ms followed by a premature stimulus with
progressively shortened coupling interval until loss of capture. Subsequently, a
single bolus injection (1 ml i.v.) of 11 nmol/kg Senktide was administered and the
measurement protocol was repeated.
Refractory periods in human left atrial appendages. Left atrial appendages
(LAA) were routinely removed from patients with atrial ﬁbrillation undergoing
minimally invasive surgical pulmonary vein isolation with an endoscopic stapling
device (Endo Gia stapler, Tyco Healthcare Group)50. The tissue samples were
transported in 100-ml cooled solution I (see modiﬁed Tyrode’s solution above)
containing 1000 IE heparin, and submerged in a tissue bath. The superfusion ﬂuid
was kept at a stable temperature of 36.5–37.5 °C and gassed with a mixture of 95%
O2 and 5% CO2 (pH 7.4). LAAs were stimulated at 100 beats per minute at 2–3
times diastolic threshold with a pulse width of 2 ms using a bipolar epicardial
electrode.
The ERP was determined by a train of 8 stimuli (at 600 ms interval) followed by
a single stimulus with progressively shortened coupling interval until loss of
capture. After an equilibrium period of 30 min, Senktide superperfusion (50–200
nM) was started, and the ERP protocol was repeated.
Single cardiomyocyte preparation. After excision of the heart from male New
Zealand White rabbits49, single left atrial and ventricular cells were isolated as
described previously, with minor modiﬁcations51,52. In short, hearts were mounted
on a Langendorff perfusion apparatus and retrogradely perfused at 37 °C through
the aorta with a modiﬁed Tyrode’s solution (see above) at a constant pressure (50
mmHg) for 15 min. Next, perfusion (50 mmHg) was changed to a nominally
calcium-free dissociation solution containing in mM: HEPES 16.8, NaCl 146.5,
KHCO3 3.3, KH2PO4 1.4, NaHCO3 1.0, MgC12 2.0, CaCl2 0.01, glucose 11.0, pH
7.3 (NaOH). After 15 min, collagenase type B (0.15 mg/ml, Roche 11088815),
collagenase type P (0.05 mg/ml, Roche 11213865), trypsine inhibitor (0.1 mg/ml,
Roche 10109878), 0.2 mg/ml hyaluronidase (Sigma H-3506), protease XIV (Sigma
H-3506) and creatine (10 mM) were added. During this last period, the heart was
perfused at a constant ﬂow in a recirculating manner. When perfusion pressure
dropped from an initial value of 50 to <2 mmHg (usually after about 30 min), the
left ventricular wall and the left atrium were cut into small pieces and further
fractionated in the enzyme-containing dissociation solution using a gyrotory water
bath shaker (25 min). During the last 10 min, 1% albumin (fatty acid free, Roche
10775835001) was added to the enzyme-containing dissociation solution. All dis-
sociation solutions were saturated with 100% O2 and the temperature was main-
tained at 37 °C. Cells were allowed to sediment and were resuspended in (enzyme-
free) dissociation solution to which 1% albumin and 1.3 mM CaCl2 was added.
Small aliquots of single cell suspension were introduced into a recording
chamber on the stage of an inverted microscope. Cells were allowed to adhere for 5
min after which superfusion was started. Single quiescent rod-shaped myocytes
with clear cross-striations and smooth surfaces were selected for measurements.
Cellular electrophysiology. Action potentials (APs) and membrane currents were
recorded at 36.5 °C with the amphotericin-B-perforated or ruptured patch clamp
technique51, using an Axopatch 200B Clamp ampliﬁer (Molecular Devices Cor-
poration, Sunnyvale, CA, USA). Voltage control, data acquisition, and analysis
were performed using custom-made software.
Series resistance was compensated for and potentials were corrected for liquid
junction potential53. Signals were low-pass ﬁltered (cutoff frequency: 5 kHz) and
digitized at 40 kHz. Cell membrane capacitance (Cm) was estimated by dividing the
time constant of the capacitive transient in response to 5 mV hyperpolarizing
voltage clamp steps from a holding potential of −40 mV, by the series resistance.
Current-clamp experiments. For AP measurements, a standard superfusion
solution was used containing (in mM): NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1.0,
glucose 5.5, HEPES 5.0, pH 7.4 (NaOH). The patch-pipettes (borosilicate glass; 1–3
MΩ) were ﬁlled with a standard pipette solution containing (in mM): K-gluconate
110, KCl 30, NaCl 5, MgCl2 1, amphotericin-B 0.22, HEPES 10, pH 7.3 (KOH).
APs were elicited at 1–4 Hz by 2-ms (1.5× diastolic stimulation threshold)
current pulses applied through the patch pipette. Resting membrane potential
(RMP), maximal upstroke velocity (Vmax), AP amplitude (APA) and AP duration
(APD) at 20%, 50% and 90% repolarization (APD20, APD50 and APD90,
respectively, were obtained from 10 consecutive APs and averaged.
Cardiomyocytes were allowed to equilibrate for a 5-min period of continuous
stimulation (1 Hz or 2 Hz) after which Sub-P (1 µM) or one of the speciﬁc
neurokinin receptor agonists (100 nM) was administered. Agonists for the NK-1R,
NK-2R and NK-3R were respectively: [Sar9,Met(O2)11]-SP33, (β-Ala)-NKA(4-10)34
and Senktide32. APs were recorded just before, and 3–5 min after application of the
neuropeptides. In dose-response experiments, Sub-P or Senktide was applied in a
cumulative sequence with 5min intervals between increments in concentration
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(Sub-P: 1, 10, 100 nM, 1, 10 µM; Senktide: 1, 2, 5 nM and 10, 20, 50 nM). The
concentration of 100 nM Senktide was applied as a singular dose.
Cardiomyocytes were pre-incubated with the speciﬁc NK-3R antagonist
Osanetant35 ((R)-N-{{3-[1-Benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-
yl}-4-phenylpiperidin-4-yl}-N-methylacetamine) (300 nM) for 10 min to study the
speciﬁcity of the Senktide-mediated APD prolongation.
To assess the contribution of TASK-1, TASK-3 and TREK-1 currents to the
action potential, APD90 was measured after application of the selective blockers
ML-36554 (100 nM), PK-THPP (100 nM)55 and Spadin56 (100 nM), respectively.
APs were recorded just before, and 3–5 min after application of the channel
blockers.
Voltage-clamp experiments. Steady-state currents, L-type Ca2+ current (ICa,L),
transient outward K+ current (Ito), Ca2+-activated Cl− current (ICl(Ca)) and
Na+–Ca2+ exchange current (INCX) were measured with solutions speciﬁed below
and using voltage-clamp protocols depicted in the corresponding ﬁgures. Steady-
state currents (current at the end of the 500-ms voltage step), Ito and ICl(Ca) were
measured using the amphotericin-B-perforated patch clamp technique with stan-
dard pipette- and superfusion-solution (see current-clamp experiments above). To
accurately determine Ito, measurements were performed in the presence of blockers
of Na+ channels (30 µM tetrodotoxin (TTX)), Ca2+ channels (0.25 mM CdCl2)
and of delayed rectiﬁer K+ channels (5 µM E-4031, 100 µM chromanol 293B).51
For ICl(Ca) measurements, 10 µM TTX and 2mM 4-aminopyridine (4-AP) was
added to the standard superfusion solution.57
ICa,L and INCX were measured using the ruptured patch clamp technique. ICa,L57
was measured with pipette solution containing (in mM): CsCl 145, K2-ATP 5,
EGTA 10, HEPES 10, pH 7.2 (NMDG-OH). The superfusion solution contained
(mM): TEA-Cl 145, CsCl 5.4, CaCl2 1.8, MgCl2 1.0, glucose 5.5, HEPES 5.0; pH 7.4
(NMDG-OH). ICa, was measured in the presence of 0.25 mM
4,4’diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS; Sigma-Aldrich, MO, USA)
to block ICl(Ca)57. INCX58 was measured with pipette solution containing (in mM):
CsCl 145, NaCl 5, Mg-ATP 10, TEA-Cl 10, EGTA 20, CaCl2 10, HEPES 10, pH 7.2
(NMDG-OH). The superfusion solution consisted of a K+-free solution to which 1
mM BaCl2, 2 mM CsCl, 5 µM nifedipine, 100 µM ouabain and 200 µM DIDS was
added to suppress membrane currents other than INCX. INCX58 was measured as
10 mM Ni2+-sensitive current during a descending voltage ramp. As the effects of
Ni2+ on INCX are reversible58, INCX measurements in the absence and presence of
Sub-P analogues were carried out in the same cell.
In voltage clamp experiments the effect of Sub-P and Senktide on the various
membrane currents was assessed at a concentration of 10 µM and 50 nM,
respectively, 3–5 min after application.
To test for the functional presence of members of the K2P family, steady-state
currents were also measured after application of the ion channel blocker ZnCl2
(100 µM).29–31
Voltage dependencies of (in)activation were determined by ﬁtting a Boltzmann
function (y= A/[1+ exp{(V–V1/2)/k}]) to the individual curves, yielding a half-
maximal voltage V1/2 (mV) and a slope factor k (mV). Time constants of
inactivation were obtained by ﬁtting current decay with a bi-exponential function
y= y0+ Afexp(−t/τf)+Asexp(–t/τs), where Af and As are the amplitudes of the fast
and slow inactivating components, and τf and τs their respective inactivation time
constants. Current densities were calculated by dividing the current amplitude
by Cm.
Cytosolic Ca2+ transients. Intracellular Ca2+ (Ca2+i) was measured in indo-1-am
loaded atrial cardiomyocytes as described previously59. Dual wavelength emission
of indo-1 was recorded ((405–440)/(505–540) nm, excitation at 340 nm) and free
Ca2+i was calculated. Ca2+i transients were elicited at 5 Hz using ﬁeld stimulation.
For determination of diastolic and systolic Ca2+i concentrations, and Ca2+i tran-
sient amplitudes, data from 10 consecutive Ca2+i transients were averaged. The
effect of Sub-P on Ca2+i was assessed at a concentration of 10 µmol/L, 3 min after
application.
Immunohistochemistry. Rabbit left atrium and human left atrial appendages were
snap-frozen in liquid nitrogen, and stored at −80 °C. Cryosections (7 µm) were
mounted on 3-aminopropyltriethoxysilane (AAS)-coated glass slides and per-
meabilized in 0.2% Triton X-100 in PBS for 20 min, where after they were blocked
in 2% bovine serum albumin for 30 min. Human cryosections were incubated
overnight with the following primary antibodies: polyclonal anti-NK3R (Immu-
nostar 20061; 1:50 dilution) and monoclonal anti-α-actinin (Sigma T7811; 1:1000).
Next, they were incubated for 90 min with secondary antibodies Alexa-conjugated
goat anti-mouse and goat anti-rabbit antibodies (1:250, Molecular Probes, Invi-
trogen) in 10% Normal Goat Serum (at room temperature). For double labelling,
sections were incubated with a mixture of primary antibodies, followed by an
appropriate mixture of secondary antibodies60. Rabbit cryosections were incubated
overnight with the polyclonal primary antibody anti-NK3R (Abcam ab123303, 1:5
dilution) directly labelled with ATTO-488 ﬂuorophore using Lightning-Link®
Rapid Conjugation System (Innova Biosciences, Cambridge, UK), to eliminate
background staining on rabbit tissue. Confocal imaging was performed using a
confocal laser scanning microscope (BioRad MRC1024) equipped with a 15-mV
Krypton/Argon laser, using the 568 and 488 excitation lines and 605DF32 and
522DF35 emission ﬁlters.
RNA-sequencing. After excision of the heart from a male New Zealand White
rabbit, tissue samples from the left atrial free wall and left atrial appendage were
isolated (4 mm3) and snap frozen in liquid nitrogen. RNA was isolated using
TruSeq (Illumina) and sequenced using Illumina Hiseq 4000 (sequence length 50,
single end). Reads are subjected to quality control (FastQC, Picard Tools), trimmed
using Trimmomatic v0.3261 and aligned to the genomes using HISAT2 (v2.0.4)62.
The genome and GTF were obtained from Ensembl (v0.89): OryCun2.0 (assembly
GCA_000003625.1) and Oryctolagus_cuniculus.OryCun2.0.89.asFasta.gtf, respec-
tively. Counts are obtained using HTSeq (v0.6.1)63. Statistical analyses are per-
formed using the edgeR64 and limma/voom65 R packages. All genes with no counts
in any of the samples are removed whilst genes with more than ﬁve reads in at least
two of the samples are kept. Count data are transformed to log2-counts per million
(logCPM), normalized by applying the trimmed mean of M-values method64 and
precision weighted using voom66. Differential expression is assessed using an
empirical Bayes moderated t-test within limma’s linear model framework,
including the precision weights estimated by voom. Resulting P-values are cor-
rected for multiple testing using the Benjamini-Hochberg false discovery rate.
Genes are re-annotated using biomaRt using the Ensembl genome databases (v91).
For ~65% of Ensembl IDs an Entrez Gene ID was retrieved using biomaRt..
Drugs. All drugs were obtained from Sigma-Aldrich (MO, USA), except for E-
4031, PK-THPP, ML-365 (Tocris, MN, USA), Sub-P (Enzo Life Sciences, NY,
USA), and TTX (Abcam Biomedicals, Cambridge, UK).
DIDS was freshly prepared as a 0.5 M and chromanol 293B as a 0.1 M stock
solution in DMSO. Nifedipine was prepared as a 5 mM stock solution in ethanol.
E-4031 and TTX were prepared as a 5 and 30 mM stock solution in distilled water.
Senktide was prepared as a 1 mM stock solution in ethanol. PK-THPP and ML-365
were prepared as a 1 mM stock solutions in DMSO. Spadin was prepared as a 1
mM Stock solution in distilled water. ZnCl2 was prepared as a 100 mM stock
solution in distilled water. All stock solutions were diluted appropriately before use.
Sub-P was freshly dissolved at its ﬁnal concentration. DIDS and nifedipine were
stored in the dark.
Statistics. The data are presented as mean ± SEM. Normality and equal variance
assumptions were tested with the Kolmogorov–Smirnov and the Levene median
test, respectively. Groups were compared using a paired Student's t-test (two-
sided), one-way repeated measures (RM) analysis of variance (ANOVA), or two-
way RM ANOVA followed by post hoc comparison using the
Student–Newman–Keuls method, where appropriate. Factor correction was
applied on APD (in Figs. 1e and 4d) and ERP (in Fig. 8 and Supplementary
Figure 5) using day of experiment and the experimental animal as session factor,
respectively67. N is number of hearts, n is number of cells. P < 0.05 was deﬁned as
statistically signiﬁcant.
Data availability
The data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. RNA sequencing data that support the ﬁndings of this
study have been deposited in Geo with the accession code GSE117801.
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